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A ribosome-related signature in peripheral blood CLL B
cells is linked to reduced survival following treatment
T Sbarrato1, E Horvilleur1, T Pöyry1, K Hill2, LC Chaplin1, RV Spriggs1, M Stoneley1, L Wilson1, S Jayne3, T Vulliamy4, D Beck3, I Dokal4,
MJS Dyer3, AM Yeomans5, G Packham5, M Bushell1, SD Wagner*,3 and AE Willis*,1
We have used polysome profiling coupled to microarray analysis to examine the translatome of a panel of peripheral blood (PB) B
cells isolated from 34 chronic lymphocytic leukaemia (CLL) patients. We have identified a ‘ribosome-related’ signature in CLL
patients with mRNAs encoding for ribosomal proteins and factors that modify ribosomal RNA, e.g. DKC1 (which encodes dyskerin,
a pseudouridine synthase), showing reduced polysomal association and decreased expression of the corresponding proteins. Our
data suggest a general impact of dyskerin dysregulation on the translational apparatus in CLL and importantly patients with low
dyskerin levels have a significantly shorter period of overall survival following treatment. Thus, translational dysregulation of
dyskerin could constitute a mechanism by which the CLL PB B cells acquire an aggressive phenotype and thus have a major role
in oncogenesis.
Cell Death and Disease (2016) 7, e2249; doi:10.1038/cddis.2016.148; published online 2 June 2016
Chronic lymphocytic leukaemia (CLL) is characterised by the
accumulation of small monoclonal B cells in the peripheral
blood (PB), lymph nodes (LN) and bone marrow (BM). The
circulating CLL cells in PB are largely arrested in the G0/G1
phase of the cell cycle; however, they undergo spontaneous
apoptosis in vitro.1 Several studies, particularly those using
heavy water, have also reported that a significant amount of
CLL B-cell proliferation occurs in the pseudofollicles. Both
proliferation and resistance to apoptosis are believed to be
governed by supporting stromal cells in the tissue microenvir-
onment, and the disease is characterised by a dynamic
imbalance between proliferation and apoptosis of neoplastic
B-lymphocytes-coexpressing CD5 and CD19 antigens.
CLL has an extremely variable outcomewith overall survival
(OS) ranging from months to decades; thus, some patients
require immediate treatment upon diagnosis, whereas
others remain asymptomatic for the whole course of the
disease. The sub-classification of CLL patients into groups
based on a number of criteria has aided the prediction of
disease outcome. For example, two early pivotal studies
demonstrated that cases where the malignant B cells
expressed somatically hypermutated immunoglobulins had a
good prognosis, whereas expression of unmutated immuno-
globulinswas associated with relatively aggressive disease.2,3
In later studies, cDNAmicroarray analysis was used to identify
gene signatures related to a number of molecular subtypes of
the disease4,5 and pathways associated with disease
evolution.6 Finally, whole-exome sequencing,7 high-density
methylation microarrays8 and RNA sequencing9 have allowed
clustering of patients into additional molecular subgroups,
independent of immunoglobulin heavy-chain variable region
(IGVH) status, which, importantly, display different outcomes
in terms of long-term survival.9
However, changes at the level of transcription are not
necessarily linked to protein expression, which can also be
controlled by regulating translation; a three-stage process
comprised of initiation, elongation and termination, where
initiation is considered to be the rate-limiting step.10 Initiation
can be controlled through changes in the expression or activity
of components of eukaryotic initiation factor (eIF) 4F complex
(comprised of eIF4E, the cap-binding protein; eIF4A1, a DEAD
box helicase and eIF4G, a scaffold protein). There are many
examples to show that aberrant translational control can
contribute to the aetiology and progression of cancer.11 For
example, altered expression/phosphorylation of eIF4E and
eIF4B (which stimulates the helicase activity of eIF4A) are
associated with poor prognosis in diffuse large B-cell
lymphoma.12,13 In CLL signalling in the LN microenvironment
promotes tumour cell proliferation14 and two recent studies
have shown the translational machinery is important in this
context.15,16 Thus stimulation of PB CLL B-cells in vitro by
either CD40L-expressing stromal cells or the B-cell receptor
(BCR) promotes translation by stimulating eIF4F complex
assembly or expression of eIF4G and eIF4A1.15,16 Following
stimulation of the BCR, it has been shown that c-Myc
protein levels are increased as a consequence of translation
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stimulation in CLL;15 however, the full repertoire of the mRNAs
(the translatome) that are controlled at this level has yet to be
defined.
The ribosome is also important in disease progression
and defects in the ribosome biogenesis pathway are also
associated with an increased cancer risk. For example, a
group of rare disorders termed ‘ribosomopathies’, which
have mutations in genes encoding for ribosomal proteins or
ribosome maturation factors, have an increased risk of
developing leukaemias and solid tumours.17 Thus, individuals
with Diamond–Blackfan anaemia with mutations in ribosomal
proteins, for example, ribosomal protein small (RPS)-19, have
a 28-fold higher incidence of acutemyeloid leukaemia than the
general population.18 Somatic mutations have also been
identified in ribosomal proteins in cancers, and mutations in
ribosomal protein large (RPL)-5 and RPL11 have been
found in patients with T-cell acute lymphoblastic leukaemia
(T-ALL),19 and in RPL10 and RPL22 in gastric and ovarian
cancers,20,21 and RPL15 and RPS15 have been identified
recently as mutated in a subset of CLL patients.22,23
Despite previous studies on translation status in CLL
following in vitro stimulation, neither the translatome nor the
role of the ribosome has been examined in circulating CLL
B-cells. Therefore, in this study, the translatome of PB CLL B
cells was identified in B cells isolated directly from 34 patients
and three normal donors by carrying out polysome profiling
coupled to cDNA microarray. Our data show that there is a
ribosome-related signature in a PB CLL B-cells with reduced
polysomal association and expression of ribosomal proteins,
and factors that modify ribosomal rRNA, including DKC1 that
encodes for the highly conserved nucleolar protein dyskerin.
The latter protein associates with the H/ACA class of small
nucleolar RNAs and functions as a pseudouridine synthase,
converting uridine to pseudouridine residues in ribosomal
RNA (rRNA) during ribosomal maturation in the nucleolus.
Importantly, we show that DKC1 protein expression is a
prognostic factor correlating with poor OS following treatment.
Results
Translational profiling of CLL patient samples. To study
the translational status of PB CLL purified B cells isolated
from patient samples, polysome profiling on cDNA micro-
arrays was performed and the data compared with control B
cells (CD45+, CD19+ and CD3− ) obtained using CD20+
selection. This subpopulation of B cells was chosen, as large
numbers of cells were required, and moreover it allowed the
comparison of our data sets with previous studies.39
Cytoplasmic lysates prepared from freshly isolated PB CLL
B cells from 34 patients or three controls were separated on a
10–60% sucrose gradient. RNA derived from fractions 1–5
(subpolysomal region) and fractions 6–10 (polysomal region)
were compared on cDNA microarrays against a commercial
universal RNA as internal reference for normalisation
(Figure 1a). Intensity signals for the subpolysomal and
polysomal composition were then used to identify mRNAs,
preferentially associated with actively translating ribosomes
in CLL patients. In brief, the data was background corrected
and normalised to a universal RNA control to extract the
logged ratio of polysomal over subpolysomal signals
(Figure 1a). The identification of significantly dysregulated
genes was performed using four different statistical tests
(Limma, Rankprod, SAM and t-test). To limit the number of
false positives identified in each statistical test, a gene was
retained as candidate for deregulation if it was significantly
identified in three out of four tests.
On average 36% fewer mRNAs were polysomally asso-
ciated in CLL when compared with the controls; 1746 mRNAs
showed a decrease in polysomal association relative to the
controls, compared with only 227 mRNAs that showed a
significant increase (Figure 1b). Interestingly, changes in
translatome did not correlate with IGVH mutational status
(Supplementary Figure 1).
Gene functional classification algorithm was applied to the
list of identified candidates to classify genes into functional
groups for the translational signature in PB CLL B cells
(Supplementary Figure 2; Figure 1c and d). The groups of
mRNAs that show reduced polysomal association included
those that encode proteins that function in RNA binding, a
large subset of ribosomal proteins and dyskerin that modifies
rRNA (Figure 1c and d; Supplementary Figure 2b and c). This
functional cluster of genes (enrichment score of 3.5) inferred
that a common pattern of translational regulation existed
across the PB CLL patients studied. Importantly, analysis of
two transcriptional data sets did not identify any enrichment in
GO terms for ribosome or protein synthesis (Supplementary
Figure 3).
There is a decrease in expression of eukaryotic initiation
factors and ribosomal proteins in CLL. Western blot
analysis was carried out on the proteins that corresponded
to a subset of mRNAs that were identified as less polysomally
associated to validate the microarray data, using the CLL
patient samples used for microarray analysis, in addition to
40 further patient samples. Three B-cell samples derived
from healthy individuals were used as controls. The data
confirmed that components of the translational machinery
identified in the translational profile as less polysomally
associated, namely, eIF4B and eIF2 alpha, showed
decreased expression relative to the controls, in addition to
eIF4E (Figure 2ai). Although the overall levels of eIF4A
appeared similar in all the CLL patients, a significant
proportion of this protein migrated at a higher molecular
weight. There is no evidence in data bases to support an
alternatively translated form of eIF4A1 and therefore the most
likely explanation is that in these cells eIF4A1 contains a
protein modification (Figure 2aii), which could be sumolya-
tion, as described.40 However, the precise type of modifica-
tion has yet to be identified. Ribosomal protein expression
was also examined and the data again confirmed the array
data, with significant decreases in expression of ribosomal
proteins, including RPS23, RPL7A, RPL9 and RPL15 (Figure
2bi, bii and c). Interestingly, dyskerin a nucleolar protein that
is involved in post-transcriptional modifications of rRNA also
exhibited decreased expression in PB CLL B cells compared
with normal B cells (Figure 2bi, bii and c). Although the overall
levels are ribosomal proteins and dyskerin expression are
significantly decreased in CLL there is variation between
patients. For example, CLL18 has expression of dyskerin and
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Figure 1 Polysome profiling of CLL patients identified a dysregulation of translation, especially within a group of ribosome-related genes. (a) General workflow of polysome
profiling. mRNAs from CLL patients or healthy controls were separated in a sucrose density gradient and analysed by spectrophotometry. Pooled fractions of subpolysomal and
polysomal regions were hybridised to cDNAmicroarrays along with an universal RNA control. (b) Represents the distribution of the translational ratios for all genes between CTRL
(x axis) and CLL (y axis; expressed as log2(polysomal/subpolysomal)). Dotted lines represent the fictive border for fold change of 2 and 0.5 (red and blue, respectively). (c) Gene
functional classification plot showing top-enriched clusters using gene ontology terms (biological processes). Under a high stringency setting, only the downregulation list yielded
significant enrichment. Dotted line represents the number of genes in each cluster. (d) Heatmap of genes in the enriched functional groups for the B-cell controls (cyan) and CLL
patients (pink)
Aberrant ribosome biogenesis in CLL
T Sbarrato et al
3
Cell Death and Disease
ribosomal proteins that is comparable to the control samples
(Figure 2bi).
Protein analysis confirms a decrease in dyskerin levels.
Decreased levels of dyskerin and ribosomal proteins
prompted us to examine other nucleolar proteins. Fibrillarin
exhibited the same decreased expression, and more impor-
tantly its expression showed similar variation to dyskerin
protein levels between patients (Figure 3a). It has been
shown previously that in CLL there is aberrant localisation
into the cytoplasm of proteins that have a role in ribosome
biogenesis, for example, nucleolin and nucleophosmin-1.41,42
Therefore, immunofluorescence studies were performed to
determine whether dyskerin was similarly affected. B cells
derived from a panel of four CLL patients were used in
conjunction with a B-cell control, purified from a healthy donor
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Figure 2 Immunoblot analysis to confirm downregulation mRNA expression by microarray results in reduced protein expression. B-cell lysates from CLL patients or healthy
controls were subjected to SDS-PAGE and western blot analysis. (ai) and (aii) show expression of proteins involved in translation initiation. (ai) and (bii) show expression of
ribosomal proteins/proteins involved in ribosome maturation. Patients samples used for (ai) and (bi) were from the same cohort as the samples used in the microarray in Figure 1,
whereas another cohort was used to produce (aii) and (bii). Tubulin and colloidal coomassie staining were used as loading controls for western samples for (ai) and (bi), where
actin was used for (aii )and (bii). (c) Western blots from a and bwere quantified and the mean expression levels were plotted for controls and CLL patients. Error bars show the S.E.M.
Significance was assessed by Student's t-test (**Po0.01, ****Po0.0001)
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(Figure 3bi). In CLL B-cells dyskerin co-localises with
fibrillarin in the nucleoli, with no detectable cytoplasmic
expression. Moreover, the immunofluorescence data con-
firmed the reduced expression of this protein in CLL
(Figure 3a). Importantly, there was a significant reduction in
size and number of nucleoli overall (Figure 3bii), consistent
with the decreased expression of ribosomal proteins
(Figure 2) and a reduced number of ribosomes.
It has been shown previously that reduced levels of dyskerin
and, as a consequence, decreased rRNA pseudouridylation,
affects ribosome–ligand interaction and translational fidelity in
both yeast and human systems.43 Moreover, in addition to
modification of rRNA and TERC by dyskerin,44 recent data
also suggest that specific subsets of mRNAs may be
pseudouridylated, including those encoding ribosomal
proteins.45
Aberrant ribosome biogenesis in CLL. Impaired pseu-
douridylation conversion and a decreased synthesis of
ribosomal proteins, may have a direct impact on rRNA
maturation and processing in CLL cells. Thus, the different
forms of rRNA species produced during the process of
maturation were studied by northern blotting in a panel of 16
CLL patients complemented with five normal counterpart
B-cell controls. Two small oligonucleotide probes comple-
mentary to the ITS1 and ITS2 allow the detection of the 45S/
41S, 30S, 21S and 18S-E forms with the ITS1 probe and the
45S/41S, 32S and 12S forms with the ITS2 probe (Figure 4a
and b). The data showed no specific blockage site in the
rRNA maturation pattern; however, the quantification showed
a slight increase in all pre-rRNA species in the CLL samples
compared with the control B-cell samples (Figure 4c). This
could imply that the rRNA maturation is slowed down in the
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Figure 3 Nucleoli are smaller in CLL cells. (a) Western blot showing expression of nucleolin and fibrillarin in CLL samples and control B cells. (bi) Immunofluorescence using
fibrillarin and dyskerin antibodies. Cells representative of one control and three CLL samples are shown. (bii) Fibrillarin immunofluorescence was quantified to estimate the
average size and number of nucleoli in CLL and control cells. The plot represents average ± S.E.M., the number of cells studied is indicated at the bottom of the bar. Significance
was assessed by Student’s t-tests (****Po0.0001)
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CLL patients presumably because of decreased pseudour-
idylation in the rRNA. It was shown using DKC1-mutant cell
line that non-pseudouridylated rRNA processing was delayed
and resulted in reduced amounts of matured 18S and 28S
rRNAs compared with the wild-type cell.46 As such, total
levels of matured 18S and 28S rRNAs were markedly
reduced in CLL patients compared with control B cells in
our study (Figure 4d), thus confirming an aberrant ribosome
biogenesis in CLL.
Circulating CLL cells are known to be essentially quiescent,
so it was possible that reduced amounts of rRNA and proteins,
as well as low dyskerin levels could simply reflect the fact that
quiescent cells have lower translation rates. To address this
point, we purified B cells from five different CLL patients and
cultivated them in presence of anti-IgM antibody to mimic
activating conditions in the lymph nodes. Interestingly,
dyskerin levels did not change in activated cells, suggesting
that low expression of dyskerin is not related to quiescence
and could be a specific feature of CLL (Supplementary
Figure 4).
Patients with reduced expression of DKC1 display
defects in ribosomal protein expression. To investigate
whether we could recapitulate our data by reducing dyskerin
expression, a siRNA-based approach was employed in
GM01953, a control B-cell line. However, in this system the
reduced dyskerin levels were only maintained for 72 h, which
was not long enough to observe any effect on ribosomal
proteins, most probably because of their long half-life (data
not shown). In support of these data, it has been shown
recently that transient depletion of DKC1 does not affect
ribosome composition.47 Therefore, to investigate whether
there was a correlation between reduced DKC1 expression
and synthesis of translation machinery, three cell lines
derived from patients with dyskeratosis congenita that had
a mutation in DKC1 gene were used as an alternative.
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Western blot analysis was performed and data show that
there was a significant decrease in the expression of RPS8,
RPS23, RPL6, RPL15 and RPL19. In addition, there was a
decrease in expression of eIF4B and interestingly the high
migrating form of eIF4A was also observed (Figure 5 and
2aii). Taken together these data suggest a link between
aberrant DKC1 function and reduced expression of some
ribosomal proteins.
Decreased dyskerin expression is associated with poor
survival following treatment. It was then important to
confirm whether dyskerin expression correlated with pre-
viously described markers of CLL and patient survival.
Dyskerin levels were examined by western analysis on 98
patient samples and these data were compared with
molecular prognostic markers in CLL (Figure 6a,
Supplementary Table 2). Although dyskerin expression was
independent from IGVH mutational status (Figure 6bi), there
was significantly lower expression in patients with 11q
deletion (targeting ATM; Figure 6bii), which is associated
with poor outcome.
To assess whether dyskerin expression was correlated with
survival in CLL, patients were divided into two groups based
on their dyskerin expression with a median cutoff. Kaplan–
Meier estimation did not show any impact of dyskerin
expression on OS (Figure 6c) or progression-free survival
(Supplementary Figure 5) in the full cohort. Kaplan–Meier
analysis was then performed to assess the patient survival
following the first treatment dependent on their dyskerin levels
(Figure 6d). The data show that patients with low dyskerin
levels had a reduced survival following chemotherapy.
Discussion
A number of early studies reported reduced ribosomal activity
in CLL patients,48–50 which correlated with a reduction in rRNA
maturation in this disease.48,51–53 In this study, the use of
translational profiling has allowed the identification of a
‘ribosome-related translational signature’ in 34 CLL patients.
GO term gene functional analysis of the translational data
yielded a set of genes containing ribosomal proteins, transla-
tion initiation factors and the pseudouridine synthase DKC1
(Figure 1). The array data was confirmed by western analysis
(Figures 2 and 3), and we provide a link between dyskerin
expression and the synthesis of a subset of ribosomal proteins.
Thus, cell lines derived from patients with mutations in DKC1
also have a reduced expression of these proteins (Figure 5).
Consistent with these changes, there is a reduction in
ribosomal maturation and fewer overall ribosomes (Figure 4).
Dyskerin is also required for telomerase activity, as it stabilises
the telomerase RNA component. Interestingly, a reduction in
DKC1 RNA levels in CLL B cells has been shown previously,
and the data suggested that this correlated with telomeric
changes in B-CLL.54 However, our data show that in PB CLL B
cells there is a reduction in DKC1 protein expression in a
subset of patient samples (Figure 2bi and ii) and no correlation
with telomere length was identified (data not shown).
Importantly, our data suggest that dyskerin expression
correlates with poor OS following chemotherapy (Figure 6).
We hypothesise that low DKC1 expression leads to an
imbalance in ribosomal proteins and when entering lymph
nodes, these changes are likely to influence response of these
B cells to the microenvironment. It has been shown previously
that mutations in individual ribosomal proteins, for example,
RPL38, although not affecting global protein synthesis rates
affect transcript-specific translational control.55 Therefore, we
speculate that in CLL the decrease in DKC1 expression,
leading to reduced synthesis of subsets of ribosomal proteins
selectively alters the translatome and that this is in turn is
associated with tumorigenesis. In this way, PB CLL B cells fits
within a group of disorders terms ribosomopathies that are
characterised by defects in ribosomal proteins or biogenesis
factors.17,55–61 In these disorders, patients usually present
with hypoproliferative defects such as BM failure; however,
with increased age they develop cancers, which are asso-
ciated with a hyperproliferative state,16 in part due to altered
translation of subsets of mRNAs. For example, in T-ALL it has
been shown that the defective ribosomes cause a reduction in
translational fidelity,55 whereas in patients with X-linked
dyskeratosis congenita initiation of translation of p53 mRNA
via its internal ribosome entry segment is impaired.56
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The identification of somatic mutations in ribosomal proteins
that are associated with cancer has refocused the identity of
the ribosome in some malignancies from a passive recipient
of aberrant signalling cues to a misfunctional cellular
machinery.62 Despite evidence that these defects are linked
to malignant transformation,17,60,63–65 the mechanisms by
which these ‘cancerous ribosomes’ participate in oncogenesis
are still not fully understood. However, we propose that in PB
CLL the ribosome deficiency is initially linked to a resting
phenotype and additional oncogenic events confer a more
aggressive phenotype.
Materials and Methods
Antibodies. Antibodies were purchased from following companies: Cell
Signaling (Danvers, MA, USA) – eIF2 alpha (cs9722), eIF4B (cs3592), eIF4E
(cs9742), RPL7a (cs2415), RPS6 (cs2217) and tubulin (cs2146) all used at 1 : 1000;
Abcam (Cambridge, UK) – eIF4A1 (ab31217) fibrillarin (ab4566), nucleolin (ab13541),
RPL6 (ab50907), RPL19 (52028), RPS16 (ab26159) and RPS23 (ab57644) all used at
1 : 1000; GeneTex (Hsinchu City, Taiwan) – RPL9 (114728) and RPL15 (101830) both
used at 1 : 1000; DKC1 (Santa Cruz, Dallas, TX, USA, sc48794, 1 : 1000); RPS8
(Abgent, San Diego, CA, USA, AP8831a, 1 : 1000); and actin (Sigma-Aldrich,
St. Louis, MO, USA, A5441, 1 : 10000).
Cell culture. Epstein–Barr transformed lymphoblatoid cell lines were derived
from dyskeratosis congenita patients using standard methods and were grown in
RPMI+20% FBS. These cell lines have been described elsewhere;24,25 however, all
three had missense mutations in the DKC1 gene giving rise to the amino-acid
substitutions p.Ala353Val (DC1107), p.Gly402Glu (DC3247) and p.Leu72Tyr
(MDH470). Control GM01953 cells were grown in RPMI1640 complemented with
15% FBS.
Sample collection and purification. CLL samples were collected under
Ethical Approval by the REC Committee and under sponsorship from the University
Hospitals of Leicester (Study UHL 08654/REC 6978: Target Identification in
Haematological Disorders). PB, collected in lithium/heparin collection tubes, was
taken from consenting CLL patients attending a weekly haematology clinic at
Leicester Royal Infirmary, UK. None of the patients had undergone treatment in the
last 3 months. Cycloheximide solution was added directly to the whole blood
immediately after it was taken, to a final concentration of 100 μg/ml, and mixed by
inversion. The samples were kept on ice during transfer before processing. Normal
donor blood products were purchased from the National Blood Service of the
National Health Service. The product consisted of leukoreduction cones produced
after routine donor platelet pharesis procedures containing white blood cells.
Mononuclear cells from CLL patients or normal donor were purified through ficoll
gradient. Normal B cells were further purified by positive selective against CD20
using Miltenyi Biotech GmbH (Bergisch Gladbach, Germany) CD20 beads and LS
columns following supplier protocol. Purity was checked by flow cytometry using
CD45, CD3 and CD19 antibodies.
Immunofluorescence. The suspension cells were incubated with freshly
prepared 4% paraformaldehyde for 10 min at room temperature. A total of 50 × 105
cells were then directly applied to glass slides, as a drop suspension of 3% BSA in
PBS. When near to dryness, the cells washed twice in PBS. The cells were
permeabilised by incubation with 0.1% Triton X-100 in PBS for 10 min at room
temperature and blocked by incubation for 30 min at room temperature with 3%
BSA in PBS. The cells were then incubated with primary antibody diluted in 3%
BSA/PBS for 1 h at room temperature for fibrillarin and overnight at 4 °C for
dyskerin. The cells were then incubated in either Alexa Fluor 568-conjugated goat
anti-rabbit IgG or Alexa Fluor 488-conjugated goat anti-mouse IgG (Invitrogen,
Thermo Fisher Scientific, Waltham, MA, USA) diluted 1 : 200 in 3% BSA/PBS for
1 h. All images were acquired using a Zeiss LSM510 (Cambridge, UK) meta laser
scanning confocal microscope.
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Figure 6 Correlation between dyskerin expression and clinical parameters (a) Summary of the clinical data for patients included in the study. (bi) Bar plot showing dyskerin
protein expression (quantified from western blots) in CLL compared with the IGVH mutational status. The P-value was calculated using Student’s t-test. (bii) Bar plot showing
dyskerin protein expression (quantified from western blots) in CLL with or without 11q deletion. The P-value was calculated using Student’s t-test. (c and d) Patients were divided
into two groups based on dyskerin expression (low dyskerin versus high dyskerin). Survival curves were generated using Kaplan–Meier approximation and significance was
estimated by log-rank P-value. Impact of dyskerin expression on overall survival was assessed on the whole cohort (c) and overall survival following treatment, estimating
treatment response (d)
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SDS-PAGE and western blotting. Cell lines extracts were prepared as
described previously.26 Pellets were lysed in lysis buffer at 96 °C before sonication
and subjected to protein quantification by BCA assay. Protein extracts were
subjected to electrophoresis on SDS-polyacrylamide gels followed by transfer to
polyvinylidene difluoride membrane (Millipore, Darmstadt, Germany). Proteins were
detected with the relevant antisera using chemiluminescent reagents.27
Sucrose density gradient centrifugation and RNA detection.
Sucrose density gradient centrifugation was used to separate ribosomes into polysomal
and subpolysomal forms. Gradients were then fractionated with continuous monitoring
at 254 nm and RNA was isolated from each fraction as described previously.28
rRNA maturation. For the detection of the different rRNA species, the northern
blotting protocol was slightly modified. An amount of 500 ng of total RNA was run in a
RNA gel and transferred to a zeta probe membrane overnight. The probe consisted of
oligonucleotides specific for the internal transcribed spacer (ITS)-1 (probe ITS1:
CCTCGCCCTCCGGGCTCCGTTAATTGATC) and ITS2 (probes ITS2d/e: GCGCGAC
GGCGGACGACACCGCGGCGTC and ITS2b: CTGCGAGGGAACCCCCAGCCGCG
CA) regions. The primers were end labelled with 1 μl of T4 PNK buffer, 50 pmol of
each probe, 10 units of T4 PNK and 1.5 μl of 32P γ-ATP for 30 min at 37 °C. The
probes were cleaned up with G25 sepharose columns and hybridised overnight at
55 °C. Northern blots were exposed to an imaging plate (Fujifilm, Tokyo, Japan)
overnight, then visualised on a molecular imager (Bio-Rad, Hercules, CA, USA).
RNA analysis. Northern analysis of RNA isolated from sucrose density gradients
was performed as described previously.28 Radiolabelled DNA hybridisation probes were
generated using the RadPrime kit according to the manufacturer’s instructions
(Invitrogen). Northern analysis on total RNA samples obtained following were performed
as described on at least three independent occasions. For RT-PCR analysis, 1 μg of
total RNA was reverse transcripted using Superscript III RNase H-Reverse transcriptase
(Invitrogen) and random primers in conditions specified by the manufacturer, then PCR
was performed on 1 μg of cDNA using 1 pmol of each primer, 2.5 μmol of dNTP mix
and 0.5 μl of Taq polymerase (Roche, Basel, Switzerland).
Preparation of fluorescently labelled cDNA for microarray
hybridisation and data analysis. The human cDNA microarrays contained
a set of ~ 10 000 human cDNA clones, manufactured in MRC Toxicology Unit
Leicester. Fluorescently labelled DNA probes were generated from equal
proportions of RNAs (~7 μg) of pooled polysomal fractions (fractions 1–5) and
pooled non-polysomal fraction (fractions 6–11) or with fixed amount of universal
commercial RNA control (UniRNA Supplier, Stratagene, San Diego, CA, USA).
Microarray slides were scanned using a GenePix 4200A microarray scanner and
GenePix Pro 5.1 software (Axon Instruments, Union City, CA, USA).
Patients and cells for studies in vitro. Patients provided written informed
consent in accordance with Ethics Committee approvals and the Declaration of
Helsinki. Heparinized PB mononuclear cells were obtained from patients attending
clinics at the Southampton General Hospital or the Royal Berkshire Hospital (both
UK; Supplementary Table S1). Diagnosis of CLL was according to the IWCLL-NCI
2008 criteria29 and the monoclonal B-lymphocyte population in the PB had a typical
IgM+IgD+ CLL phenotype in all circumstances.30 The vast majority of samples were
obtained before treatment. Where treatment for CLL had taken place, this was at
least 6 months before sample collection. IGHV usage and homology to germline,
expression of cell surface CD5, CD19, CD23 and CD38, and ZAP70 were
determined as previously described.31 sIgM signalling capacity was determined by
measuring the percentage of cells with increased intracellular Ca2+ following
stimulation with soluble goat F(ab′)2 anti-IgM and using a cutoff value of ⩾ 5%
responding cells to define samples as sIgM responsive as previously described.31
Cryopreserved CLL cells were recovered and rested for 1 h at 37 °C before use. CLL
cell viability determined by trypan blue exclusion was⩾ 90% and the median proportion
of CD5+CD19+ CLL cells was 95% (range 62–99%). For sIg stimulation, samples were
incubated with bead-bound goat F(ab′)2 anti-human IgM or control antibodies.32
Analysis of microarray data. GenePix Pro 5.1 was used to quantify
fluorescence intensities for individual spots on the microarray. Microarray data were
processed in the R-CRAN platform using the Limma package.33 The data were
background corrected and normalised between arrays against the universal RNA
control using a quantile approach. Technical replicates were averaged for each
patient. The log2 transformed ratios of polysomal over subpolysomal signal were
then subjected to a panel of four different statistical approaches: (1) « Limma »
based on model fitting in the Limma package;33 (2) « Rankprod » based on ranking
analysis in the RankProd package;34,35 (3) « SAM » based on non-parametric
approach;36 (4) and « t-test » based on a basic Student’s t-test. Genes identified as
significantly deregulated in each list were filtered to select only genes identified in at
least three of the four tests as significantly deregulated. This final list was analysed
using gene ontology (GO) annotations with DAVID37,38 for gene functional
classification using high stringency parameters and enrichment score 41.3
corresponding to a P-value o0.05. Heatmap was produced using MeV 4.0 and
network visualisation was implemented with CytoScape v3.2.1.66
Image analysis. Image quantification was performed using ImageJ software.
(National Institutes of Health, Bethesda, MD, USA).
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